1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Cue Health Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2010

Location

San Diego CA US

Primary Industry

Medical Devices & Equipment

About

Based in California, US, and founded in 2010 by co-founder Ayub Khattak and Clint Sever, Cue Health Inc. operates as a developer and manufacturer of a connected medical diagnostic system. In October 2020, the company received a government grant of USD 481 million for the production of rapid COVID-19 molecular tests. In June 2020, the company was also granted an Emergency Use Authorization (EUA) from the US Foods and Drug Administration for the use of the Cue COVID-19 Test Cartridge in conjunction with the Cue Health Monitoring System. In September 2021, Cue Health was listed on the Nasdaq Global Market under the ticker symbol "HLTH". The company offers Cue Health Monitoring System which is a portable device linked to a diagnostic platform that performs molecular testing and transforms test samples into digital results. The device is used in conjunction with the Cue Test Cartridge, the Cue Sample Wand, and the Cue Health App. Cue Health also manufactures a COVID-19 Test Cartridge, a single-use, self-contained unit that uses technology to apply the chemicals and related materials needed for molecular detection of the SARS-CoV-2 virus. Cue Health Inc. plans to scale up the manufacturing of the Cue Health Monitoring System and Cue Test Cartridges and expand its plant from 55,000 square feet to 110,000 square feet. Cue aims to be able to provide care journeys, from diagnostic testing to physician consultation to intervention, via telemedicine. Cue has five other Test Kits in late-stage technical development (influenza A/B, respiratory syncytial virus, fertility, pregnancy, and inflammation), and the firm intends to begin applying for FDA authorization or clearance in the second half of 2022. As Google is Cue's biggest customer, the two companies plan to expand their partnership in creating a respiratory bio-threat detection system.
Current Investors
ACME Capital, Flat World Partners, MaC Venture Capital

Request a demo to show more

Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare IT, Diagnostic Equipment, Monitoring Equipment, Web Applications, Connectivity Software
Website
www.cuehealth.com
Verticals
HealthTech, Mobile Apps
Company Stage
Mature
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.